Velakor
Velakor Biotherapeutics is developing CAM-6019, a novel Agrin-derived biologic therapy designed to promote cardiac regeneration and repair following heart attack and heart failure.
Modulight
Modulight is developing a transformative optogenetic platform that precisely silences pathological neural activity while preserving normal brain function.
Cliseq Ltd.
CLISEQ is developing a next-generation blood-based diagnostic platform that aims to replace invasive bone marrow biopsies with comprehensive single-cell analysis from peripheral blood.
Sub-Q Bionics Ltd.
Sub-Q Bionics Ltd transforms lymphedema treatment with a first-in-class implant for continuous fluid management.
MORF-CHIP Ltd.
MORF-CHIP Ltd. is developing a silicon-compatible platform for energy-efficient, high-performance photonic and electronic devices manufactured using standard CMOS infrastructure.
Phytolon receives FDA approval for food coloring
Phytolon, a Yeda spinoff company, has received FDA approval to market its Beetroot Red natural food coloring in the U.S., marking a major step toward commercialization in the clean-label food market.
Vyriad to Present G-LINK Platform Developed with Weizmann Institute at the 2026 ASGCT Annual Meeting
Vyriad will present new data on its G-LINK™ platform at the 2026 ASGCT Annual Meeting. G-LINK™, a modular “plug-and-play” protein adapter developed in collaboration with Prof. Menachem Rubinstein of the Weizmann Institute of Science, enables drug developers to cap and retarget existing lentiviral vectors for precise in vivo delivery, advancing next-generation CAR-T therapies.
Quantum Art Extends Series A Round to $140 Million
Quantum computing startup Quantum Art has extended its Series A financing round to $140 million, underscoring growing investor confidence in scalable quantum technologies. The company says the new funding will accelerate development of its trapped-ion quantum computing platform and expand its research and engineering teams.
Yeda’s Quantum Spinoff Q-Factor Emerges from Stealth
Quantum startup Q-Factor emerges from stealth with $24 million in seed funding and an elite scientific team.
Renewal Bio featured by Calcalist
Renewal Bio, a Yeda spinout, has been featured in Calcalist. Originating from Prof. Jacob Hanna’s lab at the Weizmann Institute of Science, the company is developing a natural bio-manufacturing platform to address the shortage of transplantable cells and tissues.
By enabling tissue regeneration and advancing cellular rejuvenation, Renewal Bio is opening new therapeutic pathways for major unmet medical needs, including bone marrow and immune system repair—demonstrating the impact of translating academic research into real-world innovation.
Pages
